<a href="https://laohu8.com/S/ONCO">Onconetix Inc.</a> Held Annual Shareholder Meeting
Onconetix Inc. held its annual meeting on December 5, 2025. Shareholders approved the issuance of up to 4,424,080 shares of Common Stock upon conversion of Series D Preferred Stock and up to 4,362,827 shares of Common Stock upon the exercise of certain warrants issued in connection with a private placement that closed on September 22, 2025. Approval was also granted for the issuance of up to 2,025,223 shares of Common Stock upon conversion of Series E Preferred Stock and up to 2,025,223 shares of Common Stock upon exercise of certain warrants related to a private placement that closed on October 1, 2025. The appointment of MaloneBailey, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. Shareholders also approved the potential adjournment of the annual meeting to solicit additional proxies if needed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-120144), on December 10, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。